Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02531126




Registration number
NCT02531126
Ethics application status
Date submitted
20/08/2015
Date registered
24/08/2015
Date last updated
18/09/2023

Titles & IDs
Public title
An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
Scientific title
A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
Secondary ID [1] 0 0
2015-001600-64
Secondary ID [2] 0 0
RPC01-3102
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Ulcerative Colitis 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Oral and Gastrointestinal 0 0 0 0
Inflammatory bowel disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Experimental: RPC0163 (Ozanimod) -

Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants with Treatment Emergent Adverse Events (TEAEs)
Timepoint [1] 0 0
From enrollment until at least 90 days after completion of study treatment
Primary outcome [2] 0 0
Number of Participants with Adverse Events (AEs)
Timepoint [2] 0 0
From enrollment until at least 90 days after completion of study treatment
Primary outcome [3] 0 0
Number of Participants with Serious Adverse Events (SAEs)
Timepoint [3] 0 0
From enrollment until at least 90 days after completion of study treatment
Primary outcome [4] 0 0
Number of Participants with TEAEs Leading to Discontinuation of Investigational Drug
Timepoint [4] 0 0
From enrollment until at least 90 days after completion of study treatment
Primary outcome [5] 0 0
Number of Participants with Adverse Events of Special Interest
Timepoint [5] 0 0
From enrollment until at least 90 days after completion of study treatment
Secondary outcome [1] 0 0
Proportion of participants with clinical remission
Timepoint [1] 0 0
Up to 6 years
Secondary outcome [2] 0 0
Proportion of participants with a clinical response
Timepoint [2] 0 0
Up to 6 years
Secondary outcome [3] 0 0
Proportion of participants with endoscopic improvement
Timepoint [3] 0 0
Up to 6 years
Secondary outcome [4] 0 0
Proportion of participants with mucosal healing
Timepoint [4] 0 0
Up to 6 years
Secondary outcome [5] 0 0
Proportion of participants with corticosteroid-free remission
Timepoint [5] 0 0
Up to 6 years
Secondary outcome [6] 0 0
Change from Baseline in complete Mayo score
Timepoint [6] 0 0
Up to 6 years
Secondary outcome [7] 0 0
Change from Baseline in partial Mayo score
Timepoint [7] 0 0
Up to 6 years
Secondary outcome [8] 0 0
Change from Baseline in 9-point Mayo score
Timepoint [8] 0 0
Up to 6 years
Secondary outcome [9] 0 0
Proportion of participants with histologic remission
Timepoint [9] 0 0
Up to 6 years
Secondary outcome [10] 0 0
Proportion of participants with clinical response in participants who had previously received anti-TNF therapy
Timepoint [10] 0 0
Up to 6 years
Secondary outcome [11] 0 0
Proportion of participants with clinical remission in participants who had previously received anti-TNF therapy
Timepoint [11] 0 0
Up to 6 years
Secondary outcome [12] 0 0
Proportion of participants with endoscopic improvement in participants who had previously received anti-TNF therapy
Timepoint [12] 0 0
Up to 6 years

Eligibility
Key inclusion criteria
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit: www.BMSStudyConnect.com



• Previously participated in a trial of RPC1063 and meets the criteria for participation in the open-label extension as outlined in the prior trial
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Receiving treatment with breast cancer resistance protein inhibitors
* Clinically relevant cardiovascular conditions
* Liver function impairment

Other protocol-defined inclusion/exclusion criteria apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
2/12/2015
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
27/02/2025
Actual
Sample size
Target
Accrual to date
Final
878
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Local Institution - 152 - Camperdown
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Illinois
Country [4] 0 0
United States of America
State/province [4] 0 0
Louisiana
Country [5] 0 0
United States of America
State/province [5] 0 0
North Carolina
Country [6] 0 0
United States of America
State/province [6] 0 0
Oklahoma
Country [7] 0 0
United States of America
State/province [7] 0 0
Oregon
Country [8] 0 0
United States of America
State/province [8] 0 0
Tennessee
Country [9] 0 0
United States of America
State/province [9] 0 0
Texas
Country [10] 0 0
Belarus
State/province [10] 0 0
Vitebsk
Country [11] 0 0
Belgium
State/province [11] 0 0
Leuven
Country [12] 0 0
Bulgaria
State/province [12] 0 0
Sofia
Country [13] 0 0
Germany
State/province [13] 0 0
Berlin
Country [14] 0 0
Germany
State/province [14] 0 0
Frankfurt
Country [15] 0 0
Greece
State/province [15] 0 0
Athens
Country [16] 0 0
Hungary
State/province [16] 0 0
Balatonfured
Country [17] 0 0
Hungary
State/province [17] 0 0
Debrecen
Country [18] 0 0
Israel
State/province [18] 0 0
Rechovot
Country [19] 0 0
Italy
State/province [19] 0 0
Toscana
Country [20] 0 0
Romania
State/province [20] 0 0
Bucharest
Country [21] 0 0
Slovakia
State/province [21] 0 0
Bardejov
Country [22] 0 0
Ukraine
State/province [22] 0 0
Kharkiv
Country [23] 0 0
United Kingdom
State/province [23] 0 0
Greater London
Country [24] 0 0
United Kingdom
State/province [24] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Celgene
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate the long-term safety and efficacy of RPC1063 in participants with moderately to severely active ulcerative colitis. Only those participants who have previously participated in a trial of RPC1063, being either RPC01-3101 or completed at least 1 year of the open-label period of RPC01-202 will be eligible.
Trial website
https://clinicaltrials.gov/study/NCT02531126
Trial related presentations / publications
Sandborn WJ, Feagan BG, Hanauer S, Vermeire S, Ghosh S, Liu WJ, Petersen A, Charles L, Huang V, Usiskin K, Wolf DC, D'Haens G. Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study. J Crohns Colitis. 2021 Jul 5;15(7):1120-1129. doi: 10.1093/ecco-jcc/jjab012.
Public notes

Contacts
Principal investigator
Name 0 0
Bristol-Myers Squibb
Address 0 0
Bristol-Myers Squibb
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02531126